Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Comparative Immunology, Microbiology and Infectious Diseases is Scopus-indexed (Q1, CiteScore 4.4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Ltd.
Checked against the index lists dated .
ISSN 0147-9571Verify ISSN ↗1878-1667Verify ISSN ↗
Publisher: Elsevier Ltd
Cost to publish: About US$3,550 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Veterinary (all) | 19 / 204 | 90th | Q1 |
| Infectious Diseases | 143 / 361 | 60th | Q2 |
| Immunology and Allergy | 128 / 234 | 45th | Q3 |
| Microbiology | 107 / 194 | 45th | Q3 |
| Immunology | 143 / 243 | 41st | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1978–present, best quartile Q1, CiteScore 4.4.
Comparative Immunology, Microbiology and Infectious Diseases is Q1 in Veterinary (all) (rank 19 of 204), Q2 in Infectious Diseases (rank 143 of 361) and Q3 in Immunology and Allergy (rank 128 of 234), by CiteScore 2025. It is ranked in 5 subject areas in all.
Comparative Immunology, Microbiology and Infectious Diseases is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.4, which places it in quartile Q1 at the 90th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.596, quartile Q1, with an H-index of 72.
The publisher lists an article processing charge of about US$3,550 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Comparative Immunology, Microbiology and Infectious Diseases is published by Elsevier Ltd. Its print ISSN is 0147-9571 and its online ISSN is 1878-1667.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Comparative Immunology, Microbiology and Infectious Diseases has an h-index of 87 and a 2-year mean of 2.2 citations per paper (OpenAlex). Its Scopus CiteScore is 4.4, quartile Q1. On 2-year citations it ranks #30 of 197 Scopus journals in Veterinary (all).
Comparative Immunology, Microbiology and Infectious Diseases published 85 papers in 2025; its busiest recent year was 2019 with 159. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from Brazil (14.3%), China (11.1%) and Algeria (10.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.5 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.